The outcome of heart failure in women: a study from a tertiary heart function clinic

Abeer Bakhsh1, Alaa AlSayed1, Mohammed AlTamimi1

  • 1Advance Heart Failure, Prince Sultan Cardiac Centre Riyadh, Saudi Arabia.

Insights

Women with heart failure (HF) often present with reduced ejection fraction and dilated cardiomyopathy, facing high rates of obesity and chronic disease. Advanced HF therapies are underutilized in this population, necessitating improved access to specialized care.

Area of Science:

  • Cardiology
  • Women's Health
  • Cardiovascular Disease

Background:

  • Women experience unique cardiovascular disease risk factors and mortality rates.
  • Heart failure (HF) prevalence in women is influenced by factors like age, pregnancy, and menopause.
  • Further understanding of HF in women regarding etiology, management, and outcomes is crucial.

Purpose of the Study:

  • To analyze the characteristics, causes, and outcomes of heart failure in women.
  • To evaluate the prevalence of comorbidities and adverse pregnancy events in women with HF.
  • To assess the utilization of advanced HF therapies and referral patterns in women.

Main Methods:

  • Retrospective study of 561 women diagnosed with HF at a tertiary cardiac center's heart function clinic.
  • Analysis of patient demographics, HF diagnosis, comorbidities (diabetes, hypertension, obesity), and pregnancy history.
  • Review of treatment patterns, left ventricular recovery, and patient outcomes including chronic HF, heart transplant, and mortality.

Main Results:

  • The majority of women (84%) presented with HF with reduced ejection fraction (HFrEF), most commonly due to dilated cardiomyopathy (54.2%).
  • High prevalence of comorbidities including diabetes (48.5%), hypertension (47.6%), and obesity (59% with BMI ≥ 30).
  • Significant rates of adverse pregnancy events (miscarriages 38.6%) and a substantial proportion of women living with chronic HF (42.8%), with low heart transplant rates (3.75%).

Conclusions:

  • Women are underrepresented in specialized heart function clinics, indicating low referral rates.
  • Obesity is highly prevalent, and most women experience chronic HF, yet advanced therapy consideration remains low.
  • There is a critical need to improve access to specialized care and advanced HF therapies for women.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
342
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
396
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594